Table 1 Baseline characteristics of patients

Male sex (%)

14 (48.3)

Age at disease onset (mean ± SD, years old)

36 ± 14

Body weight (kg)

 Mean ± SD

51.7 ± 11.1

 Range

32.0–78.0

Tobacco, nonsmoker (%)

22 (75.9)

Alcohol, nondrinker (%)

17 (58.7)

Age at initiation of anti-TNFα agent (mean ± SD, years old)

42 ± 14

Disease duration before anti-TNFα agent

(mean ± SD, years)

6 ± 9

Type of anti-TNFα agent (IFX/ADA) administered

16/13

Major symptoms

 Ocular lesions (%)

9 (31.0)

 Skin lesions (%)

12 (41.4)

 Oral ulcers (%)

28 (96.6)

 Genital ulcers (%)

10 (34.5)

Minor symptoms

 Arthritis (%)

8 (27.6)

 Vascular involvement (%)

1 (3.4)

HLA-B51 positivity (n = 21, %)

5/21 (23.8)

HLA-A26 positivity (n = 21, %)

3/21 (14.3)

Concomitant medication administered with the anti-TNFα agent

–

 Systemic corticosteroids (%)

20 (69.0)

≧ 20 mg corticosteroids (%)

9 (31.0)

 5-Aminosalicylic acid (%)

11 (37.9)

 CyA (%)

2 (6.9)

 MTX (%)

3 (10.3)

 Azathioprine/6-mercaptopurine (%)

18 (62.1)

 Colchicine (%)

16 (55.2)

Previous major abdominal surgery (%)

4 (13.8)

baseline Global GI symptoms score (mean ± SD); score 0–4

1.69 ± 1.4

Baseline CRP level (mean ± SD, mg/dL)

1.81 ± 3.8